Multifunctional magnetic Fe3O4 nanoparticles combined with chemotherapy and hyperthermia to overcome multidrug resistance

Ren, Yanru; Chen, Baoan

doi:10.2147/ijn.s29357

Cited by 33 publications

(11 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study using chronic myeloid leukemia tumors (K562/A02) in mice in combination with magnetic hyperthermia (40 minutes, 43°C) reported comparable results in relation to the breast cancer model we used in this study. 23 Moreover, the use of an exogenous heat source as a more indirect way of heat application by water bath hyperthermia (60 minutes, 43°C) showed only a slight decrease of BCL2 4 hours after treatment in vivo. 18 In vitro BCL2 protein is known to be slightly downregulated in tumor cells immediately after heat stress (180 minutes, 42.5°C).…”

Section: Discussionmentioning

confidence: 98%

Magnetic thermoablation stimuli alter BCL2 and FGF-R1 but not HSP70 expression profiles in BT474 breast tumors

Stapf¹,

Pömpner²,

Kettering³

et al. 2015

IJN

View full text Add to dashboard Cite

Magnetically induced heating of magnetic nanoparticles (MNP) in an alternating magnetic field (AMF) is a promising minimal invasive tool for localized tumor treatment that eradicates tumor cells by applying thermal stress. While temperatures between 42°C and 45°C induce apoptosis and sensitize the cells for chemo- and radiation therapies when applied for at least 30 minutes, temperatures above 50°C, so-called thermoablative temperatures, rapidly induce irreversible cell damage resulting in necrosis. Since only little is known concerning the protein expression of anti-apoptotic B-cell lymphoma 2 (BCL2), fibroblast growth factor receptor 1 (FGF-R1), and heat shock protein (HSP70) after short-time magnetic thermoablative tumor treatment, these relevant tumor proteins were investigated by immunohistochemistry (IHC) in a human BT474 breast cancer mouse xenograft model. In the investigated sample groups, the application of thermoablative temperatures (<2 minutes) led to a downregulation of BCL2 and FGF-R1 on the protein level while the level of HSP70 remained unchanged. Coincidently, the tumor tissue was damaged by heat, resulting in large apoptotic and necrotic areas in regions with high MNP concentration. Taken together, thermoablative heating induced via magnetic methods can reduce the expression of tumor-related proteins and locally inactivate tumor tissue, leading to a prospectively reduced tumorigenicity of cancerous tissues. The presented data allow a deeper insight into the molecular mechanisms in relation to magnetic thermoablative tumor treatments with the aim of further improvements.

show abstract

Section: Discussionmentioning

confidence: 98%

Magnetic thermoablation stimuli alter BCL2 and FGF-R1 but not HSP70 expression profiles in BT474 breast tumors

Stapf¹,

Pömpner²,

Kettering³

et al. 2015

IJN

View full text Add to dashboard Cite

show abstract

“…Magnetic Fe 3 O 4 nanoparticles are often employed because they give possibility to control the transport by applying external magnetic fields. Such magnetic nanoparticles conjugated with DNR were reported to induce apoptosis of cancer cell lines [11–12]. Other examples of nanoparticles include titanium dioxide (TiO 2 ) and gold nanoparticles (AuNPs) [13–14].…”

Section: Introductionmentioning

confidence: 99%

Comparison of the interactions of daunorubicin in a free form and attached to single-walled carbon nanotubes with model lipid membranes

Matyszewska¹

2016

Beilstein J. Nanotechnol.

View full text Add to dashboard Cite

SummaryIn this work the interactions of an anticancer drug daunorubicin (DNR) with model thiolipid layers composed of 1,2-dipalmitoyl-sn-glycero-3-phosphothioethanol (DPPTE) were investigated using Langmuir technique. The results obtained for a free drug were compared with the results recorded for DNR attached to SWCNTs as potential drug carrier. Langmuir studies of mixed DPPTE–SWCNTs-DNR monolayers showed that even at the highest investigated content of the nanotubes in the monolayer, the changes in the properties of DPPTE model membranes were not as significant as in case of the incorporation of a free drug, which resulted in a significant increase in the area per molecule and fluidization of the thiolipid layer. The presence of SWCNTs-DNR in the DPPTE monolayer at the air–water interface did not change the organization of the lipid molecules to such extent as the free drug, which may be explained by different types of interactions playing crucial role in these two types of systems. In the case of the interactions of free DNR the electrostatic attraction between positively charged drug and negatively charged DPPTE monolayer play the most important role, while in the case of SWCNTs-DNR adducts the hydrophobic interactions between nanotubes and acyl chains of the lipid seem to be prevailing. Electrochemical studies performed for supported model membranes containing the drug delivered in the two investigated forms revealed that the surface concentration of the drug-nanotube adduct in supported monolayers is comparable to the reported surface concentration of the free DNR incorporated into DPPTE monolayers on gold electrodes. Therefore, it may be concluded that the application of carbon nanotubes as potential DNR carrier allows for the incorporation of comparable amount of the drug into model membranes with simultaneous decrease in the negative changes in the membrane structure and organization, which is an important aspect in terms of side effects of the drug.

show abstract

“…Wang and colleagues reported a multifunctional nanoparticle composed of supraparamagnetic Fe 3 O 4 nanoparticles and chemotherapeutics DNR and 5-BrTet (Fe 3 O 4 -MNP-DNR-5-BrTet), an inhibitor of P-gp and anti-apoptotic proteins, for concomitant chemotherapy and hyperthermia [105] (Figure 14). Significant temperature increase was observed in tumors treated by both Fe 3 O 4 -MNP and Fe 3 O 4 -MNP-DNR-5-BrTet.…”

Section: Iron Oxide Nanoparticles For Combination Therapymentioning

confidence: 99%

“…(b) Tumor inhibition rate of mice at day 4 after treatment. Reproduced with permission from reference [105]. Copyright (2012), with permission from Elsevier.…”

Section: Figurementioning

confidence: 99%

Hybrid nanoparticles for combination therapy of cancer

Lin

2015

Journal of Controlled Release

125

View full text Add to dashboard Cite

Nanoparticle anticancer drug delivery enhances therapeutic efficacies and reduces side effects by improving pharmacokinetics and biodistributions of the drug payloads in animal models. Despite promising preclinical efficacy results, monotherapy nanomedicines have failed to produce enhanced response rates over conventional chemotherapy in human clinical trials. The discrepancy between preclinical data and clinical outcomes is believed to result from the less pronounced enhanced permeability and retention (EPR) effect in and the heterogeneity of human tumors as well as the intrinsic/acquired drug resistance to monotherapy over the treatment course. To address these issues, recent efforts have been devoted to developing nanocarriers that can efficiently deliver multiple therapeutics with controlled release properties and increased tumor deposition. In ideal scenarios, the drug or therapeutic modality combinations have different mechanisms of action to afford synergistic effects. In this review, we summarize recent progress in designing hybrid nanoparticles for the co-delivery of combination therapies, including multiple chemotherapeutics, chemotherapeutics and biologics, chemotherapeutics and photodynamic therapy, and chemotherapeutics and radiotherapy. The in vitro and in vivo anticancer effects are also discussed.

show abstract

Multifunctional magnetic Fe3O4 nanoparticles combined with chemotherapy and hyperthermia to overcome multidrug resistance

Cited by 33 publications

References 38 publications

Magnetic thermoablation stimuli alter BCL2 and FGF-R1 but not HSP70 expression profiles in BT474 breast tumors

Magnetic thermoablation stimuli alter BCL2 and FGF-R1 but not HSP70 expression profiles in BT474 breast tumors

Comparison of the interactions of daunorubicin in a free form and attached to single-walled carbon nanotubes with model lipid membranes

Hybrid nanoparticles for combination therapy of cancer

Contact Info

Product

Resources

About